Introduction to Argus Product Tab Screen in Pharmacovigilance or Drug Safety of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
2. Product Information:
Spontaneous/Literature:
At least one Novartis drug should be entered as suspect
Two or more Novartis drugs can be entered as co-
suspect
Only one case will be created
Concomitant Novartis drugs are coded with WHO drug
dictionary
2
01/29/17Katalyst Healthcares & Life Sciences
3. Concomitant Medication & Treatments
All co-medications should be entered in the Products
screen and marked concomitant
All drugs used to treat the adverse event should be
entered in the Products screen and marked treatment
Use the WHO Drug Coding List to select product name -
using the encode button for both concomitant and
treatment medication
3
01/29/17Katalyst Healthcares & Life Sciences
4. Coding Medication:
Product Name and Generic Name fields are
automatically populated from data entered in the
book-in screen
Indication will also be automatically populated as
derived from book-in coding if the drug is coded to an
indication
Therefore, ensure information is correct prior to product
selection
4
01/29/17Katalyst Healthcares & Life Sciences
5. Trade Name Lookup
The most critical fields are:
• Product
• Ingredient
• Formulation
• Indication
5
01/29/17Katalyst Healthcares & Life Sciences
6. Trade Name Lookup
The most critical fields are:
• Product
• Ingredient
• Formulation
• Indication
6
01/29/17Katalyst Healthcares & Life Sciences
7. Coding of Novartis Drugs:
Under country delete the country name and type in
- World1 to look for the local trade name
- World to look for the international trade name
- NH (for Novartis Pharma Headquarters) to look for the generic name
- NCH (Novartis Consumer Health) to look for products ‘owned’ by Consumer
Health.
- NVO (Novartis Ophthalmics) or ‘o-‘ to look for Ophtha products.
- NGX (Novartis Generics) to look for products ‘owned’ by Novartis Generics.
7
01/29/17Katalyst Healthcares & Life Sciences
9. Co-meds and Treatment meds
Therapy Details:
Enter for concomitant and treatment medications
Do not enter procedures, surgery, and non-drug
therapy as treatment
9
01/29/17Katalyst Healthcares & Life Sciences
10. Product Information:
Concentration Units:
should be used to capture strength of suspect formulation, if
provided
Do not use this field for products which have an indication
linked to the product selection ie. Neoral
Formulation:
should be left unchanged
10
01/29/17Katalyst Healthcares & Life Sciences
11. Dosage Information:
Suspect/Concomitant Medication:
For all cases enter all dosage information up until the onset of
the event
Treatment Medication:
For all cases enter all known dosage information relevant to
the treatment of the event
11
01/29/17Katalyst Healthcares & Life Sciences
12. Dosage Information:
Multiple dosage regimens:
Enter in chronological order
Relevant dosage changes leading up to an event/episode
(recurrent events) and during an event/episode can be added
up until the final resolution of the event/episode
Dosage range:
when citing a range, use the minus key, not a dash (dashes do
not print out on the MedWatch form)
12
01/29/17Katalyst Healthcares & Life Sciences
13. Dosage Regimens:
Stop dates:
should not be entered where the patient has died
while on drug therapy
Dose Description:
should always be filled in, if appropriate, as it maps
to regulatory forms
13
01/29/17Katalyst Healthcares & Life Sciences
14. Dosage Regimens:
Patient Route of Administration:
select the appropriate value from the drop down list, which
reflects the patient’s route of administration i.e. oral or type o
several times.
Parent Route of Administration:
used in Baby cases to enter mother information of route of
administration
14
01/29/17Katalyst Healthcares & Life Sciences
15. Action Taken
Specifically refers to the suspect product,
not the event as a whole
Only one action item can be entered
If more than one action, use most relevant term- the discontinued
option should have higher priority
15
01/29/17Katalyst Healthcares & Life Sciences
16. Dechallenge:
Tick the appropriate checkbox:
• Positive: drug was stopped and the event/symptoms
improved/disappeared
• Negative: drug was stopped and the event/symptoms
did not improve/go away or patient has
sequelae
• N/A: drug was not stopped
• Unknown: the result of the dechallenge is unknown
Definition: when the drug has been
interrupted because of the event...
16
01/29/17Katalyst Healthcares & Life Sciences
17. Rechallenge:
Tick the appropriate checkbox:
• Positive: drug was re-introduced and symptoms reappeared
• Negative: drug was re-introduced and symptoms did not
reappear
• N/A: drug was not re-introduced
• Unknown: The result of the rechallenge is unknown
Definition: …if drug is then re-introduced
17
01/29/17Katalyst Healthcares & Life Sciences
At least one Novartis drug should be entered as suspect. The Novartis dictionary should be used for coding . Use yellow select button in Product name field to access Novartis dictionary.
More than one Novartis drug can be entered as co-suspect. Tick suspect radiobuton in Product field. Use Novartis dictionary to select products.
Use of Novartis dictionary allows correct expediting of case.
All comedications which are relevant to the assessment of the adverse event should be entered.
All products will be coded using WHO.
For open and unblinded triials enter in the ‘administered drug’ field that no medication was given